A director at Becton Dickinson & Co sold 2,838 shares at 223.330USD and the significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
Moody's Ratings (Moody's) commented that Becton, Dickinson and Company's (Baa2 stable) announcement that it had reached an agreement to resolve the vast majority of its US product liability lawsuits involving hernia repair devices is credit negative. Per the settlement terms, Becton will make paymen...
Moody's Ratings (Moody's) commented that Becton, Dickinson and Company's (Baa2 stable) announcement that it had reached an agreement to resolve the vast majority of its US product liability lawsuits involving hernia repair devices is credit negative. Per the settlement terms, Becton will make paymen...
Moody's Ratings commented that Becton, Dickinson and Company's (BD) announcement that it will acquire the critical care division of Edwards Lifesciences Corporation for a total enterprise value of $4.2 billion will bolster BD's presence in the critical care setting and is credit positive because of ...
Moody's Investors Service ("Moody's") assigned Baa2 ratings to the new USD and EUR denominated senior unsecured notes offering of Becton, Dickinson and Company ("BD"). Net proceeds from the notes will be used to repay existing indebtedness and to cover associated fees and expenses. All other ratings...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.